Personalized vaccine therapy combined with immune checkpoint inhibitors for aggressive breast cancer
Official title: Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
Funded at Metaclipse Therapeutics Corporation · NIH-10489848 · Data updated 2026-11-12
This study is testing a new personalized vaccine treatment for triple negative breast cancer that uses pieces from your own tumor to help boost your immune system and fight the cancer better.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Metaclipse Therapeutics Corporation NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 16, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $938,597 |
| NIH project number | 5R44CA257278-02 |
| Project ID | NIH-10489848 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with triple negative breast cancer who have limited treatment options.
✕Less likely to help
Patients with other types of breast cancer or those who have already responded well to existing therapies may not benefit from this research.
What this research studies
This research investigates a new treatment approach for triple negative breast cancer (TNBC), which is known for its aggressive nature and limited effective therapies. The study focuses on developing a personalized vaccine immunotherapy that uses tumor membrane vesicles derived from a patient's own tumor tissue, combined with immune checkpoint inhibitors. By targeting the unique antigens present in each patient's tumor, this approach aims to enhance the immune response against cancer cells. Patients will receive this novel therapy to potentially improve their treatment outcomes.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with triple negative breast cancer, potentially improving survival rates.
How similar studies have gone: While the approach of personalized vaccine therapy is innovative, similar strategies have shown promise in other cancer types, indicating potential for success in this area.
Where this research is happening
-
Metaclipse Therapeutics Corporation
Atlanta, United States Active
Researchers
- Principal investigator: Pack, Christopher D — Metaclipse Therapeutics Corporation
- Study coordinator: Pack, Christopher D
Related research
Other NIH-funded projects on the same topics.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
Determinants of Response to DNA-Damaging Radiation and Immunotherapy in Triple-Negative Breast Cancer
This grant explores why some people with triple-negative breast cancer respond to a combo of radiation, chemotherapy, and immunotherapy and why others don’t, to guide more personalized treatment.
-
New immunotherapy combo for hard-to-treat triple-negative breast cancer
Aims to test a combination immunotherapy with JNK inhibitors to improve treatment for people with triple-negative breast cancer.
-
Reprogrammed exosome immunotherapy for triple-negative breast cancer
A new treatment approach uses engineered exosomes to stimulate the immune system to fight triple-negative breast cancer in patients.
-
Engineered CD4+ T cells targeting KK‑LC‑1 for triple‑negative breast cancer
This project creates engineered CD4+ T cells that recognize the KK‑LC‑1 tumor antigen to help people with HLA‑DR13-positive triple‑negative breast cancer.
-
Why some triple-negative breast cancers respond to radiation plus immunotherapy and others resist
This project looks at whether patterns of tumor cell death and immune signals can predict and improve responses to radiation combined with anti-PD1 immunotherapy for people with early-stage triple-negative breast cancer that has spread to lymph nodes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.